| 000 | 01778 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513191439.0 | ||
| 264 | 0 | _c19990903 | |
| 008 | 199909s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.1999.17.1.338 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHesketh, P J | |
| 245 | 0 | 0 |
_aRandomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cJan 1999 |
||
| 300 |
_a338-43 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiemetics _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBenzene Derivatives _xadverse effects |
| 650 | 0 | 4 |
_aCisplatin _xadverse effects |
| 650 | 0 | 4 |
_aDexamethasone _xtherapeutic use |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGranisetron _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeurokinin-1 Receptor Antagonists |
| 650 | 0 | 4 |
_aVomiting _xchemically induced |
| 700 | 1 | _aGralla, R J | |
| 700 | 1 | _aWebb, R T | |
| 700 | 1 | _aUeno, W | |
| 700 | 1 | _aDelPrete, S | |
| 700 | 1 | _aBachinsky, M E | |
| 700 | 1 | _aDirlam, N L | |
| 700 | 1 | _aStack, C B | |
| 700 | 1 | _aSilberman, S L | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 17 _gno. 1 _gp. 338-43 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1999.17.1.338 _zAvailable from publisher's website |
| 999 |
_c10415862 _d10415862 |
||